Emma C. Morris
Department of Haematology
University College Hospital
98 Chenies Mews
London WC1E 6HX
UK
Name/email consistency: high
- Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. Morris, E.C., Mackinnon, S. Best. Pract. Res. Clin. Haematol (2005)
- Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Morris, E., Mackinnon, S. Transfus. Apher. Sci. (2005)
- Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A., Mackinnon, S. Blood (2004)
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Morris, E.C., Rebello, P., Thomson, K.J., Peggs, K.S., Kyriakou, C., Goldstone, A.H., Mackinnon, S., Hale, G. Blood (2003)